Vifor & American Regent v. Dr. Reddy’s: Injectafer® Patent Dispute Dismissed
Vifor (International) AG and American Regent, Inc. asserted six patents covering ferric carboxymaltose injection (Injectafer®) against Dr. Reddy’s Laboratories in the District of New Jersey. After 404 days of litigation, the parties jointly stipulated to dismiss all claims without prejudice, with each side bearing its own costs.
Six-patent Injectafer® ANDA battle ends in mutual no-cost dismissal
Vifor (International) AG, the Swiss pharmaceutical group, and its U.S. commercial partner American Regent, Inc. filed suit on 7 June 2024 in the U.S. District Court for the District of New Jersey against Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. The complaint alleged infringement of six U.S. patents — US11433091B2, US11478502B2, US7754702B2, US8895612B2, US11364260B2, and US7612109B2 — all relating to Injectafer®, a ferric carboxymaltose intravenous iron injection marketed at concentrations from 100 mg/2 mL up to 1 g/20 mL.
The action resolved on 16 July 2025 when both sides executed a stipulation and order of dismissal. Under the agreed terms, all claims, counterclaims, and demands were dismissed without prejudice, and neither party is entitled to costs, disbursements, or attorneys’ fees. The parties also expressly waived any right to appeal or seek relief from the stipulation, and the order is expressed to finally resolve the action between them — a structurally unusual combination of ‘without prejudice’ dismissal with a finality and appeal-waiver clause.
The 404-day duration — from filing through dismissal — suggests the parties conducted meaningful pre-trial activity before reaching resolution, though the public record does not disclose whether a licensing agreement, development concession, or commercial arrangement underlies the settlement. The without-prejudice designation technically preserves plaintiffs’ ability to refile on the same patents, though the appeal waiver and finality language constrain that optionality in practice. The absence of any cost award to either side is consistent with a negotiated outcome where neither party conceded infringement or invalidity.
Filing to Case Dismissed in 404 days
404 days — longer than the median ANDA patent case first dismissal in D.N.J.
Stipulated dismissal without prejudice: what the order means for both parties
Stipulated dismissal without prejudice — not a merits ruling
A stipulated dismissal without prejudice terminates the immediate proceeding but does not adjudicate the validity or infringement of any patent. Neither party obtained a judicial finding on the merits. The express appeal waiver in this stipulation is unusual alongside a without-prejudice designation — it closes the current action definitively while leaving the underlying IP rights unresolved.
No merits adjudicationPlaintiffs retain all six patents with enforceability intact
Because dismissal is without prejudice and no invalidity finding was made, Vifor and American Regent retain full enforceability of all six asserted patents. They could, in principle, refile against Dr. Reddy’s or assert the same patents against other generic applicants. However, the appeal waiver and finality language mean they cannot revisit this specific action. Their exclusivity position on Injectafer® formulations remains legally unchanged.
Patents remain enforceableDr. Reddy’s exits without infringement finding — but faces unresolved IP risk
Dr. Reddy’s avoids an adverse infringement judgment and is not bound by any injunction or damages award. Critically, no invalidity ruling was secured. This means the six patents remain barriers to market entry. If Dr. Reddy’s pursues its ANDA and launches, it would face the same patent portfolio without the benefit of any court-adjudicated invalidity defence from this case.
No invalidity ruling securedInjectafer® patent thicket survives — generic entry timeline uncertain
With six patents spanning formulation, composition, and method-of-use claims still enforceable, the commercial pathway for generic ferric carboxymaltose injection remains technically obstructed. Other generic applicants targeting Injectafer® should note that these patents survived this litigation cycle without challenge. This outcome is consistent with a negotiated commercial arrangement but market entry risk persists for any party not holding a licence.
Six patents uncontestedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Vifor (International), AG | Company | Swiss pharmaceutical group — holder of six ferric carboxymaltose injection patentsSearch in Eureka ↗ |
| Co-Plaintiff | American Regent, Inc. | Company | Search in Eureka ↗ |
| Defendant | Dr. Reddy’s Laboratories, Ltd. | Company | Indian-American generic pharmaceutical manufacturer seeking Injectafer® ANDA entrySearch in Eureka ↗ |
| Co-Defendant | Dr. Reddy’s Laboratories, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Brian John Forsatz | Attorney | Counsel for Vifor (International), AGSearch in Eureka ↗ |
| Plaintiff counsel | Cynthia Stencel Betz | Attorney | Counsel for Vifor (International), AGSearch in Eureka ↗ |
| Plaintiff counsel | Mark M. Makhail | Attorney | Counsel for Vifor (International), AGSearch in Eureka ↗ |
| Plaintiff counsel | MICHAEL FREDERICK WERNO | Attorney | Counsel for Vifor (International), AGSearch in Eureka ↗ |
| Plaintiff law firm | Gibson, Dunn & Crutcher, LLP | Law Firm | Representing Vifor (International), AGSearch in Eureka ↗ |
| Plaintiff law firm | Mccarter & English, LLP | Law Firm | Representing Vifor (International), AGSearch in Eureka ↗ |
| Plaintiff law firm | QUINN EMANUAL URQUHART & SULLIVAN, LLP | Law Firm | Representing Vifor (International), AGSearch in Eureka ↗ |
| Defendant counsel | Gregory D. Miller | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Jenna Z. Gabay | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | MARCUS O. TUBIN | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Timothy P. Gonzalez | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant law firm | Rivkin Radler, LLP | Law Firm | Representing Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation’s language — ‘dismissed without prejudice and without costs’ combined with an express appeal waiver — reflects a carefully negotiated exit rather than a simple procedural withdrawal. The without-prejudice designation leaves the door open for refiling, but the mutual appeal waiver and finality clause functionally close this chapter. No claim construction, no invalidity ruling, and no damages finding appear in the record, meaning neither side can point to a judicial determination that binds future proceedings against other parties.
US11433091B2 — Ferric carboxymaltose formulation and method patents
The six asserted patents — US11433091B2, US11478502B2, US7754702B2, US8895612B2, US11364260B2, and US7612109B2 — collectively cover the ferric carboxymaltose compound, its formulation, and methods of use underlying Injectafer®, a high-dose intravenous iron therapy. The portfolio spans a range of application dates and claim types, from core composition claims to newer method-of-use claims, building a layered ‘patent thicket’ characteristic of complex injectable biologics and specialty pharmaceuticals.
Ferric carboxymaltose holds a distinctive clinical profile as a high-dose, single-infusion IV iron agent used in iron deficiency anaemia, giving Injectafer® significant commercial value and making its patent protection commercially critical. The portfolio’s breadth — six patents across multiple application families — reflects a deliberate lifecycle management strategy. For any generic entrant navigating an ANDA pathway, each of these patents represents a discrete invalidity or non-infringement challenge with independent claim scope, substantially increasing the litigation burden and risk exposure.
Should your R&D or regulatory team run an FTO against these Injectafer® patents?
Any pharmaceutical company developing, manufacturing, or seeking ANDA approval for a ferric carboxymaltose IV iron injection product should treat all six patents asserted in this case as active enforcement risks. The dismissal without prejudice leaves these patents fully enforceable, with no invalidity findings on record. Companies in formulation development, generic API sourcing, or biosimilar-adjacent injectable iron programmes should conduct a formal FTO before advancing to IND or ANDA filing.
PatSnap Eureka’s FTO Search Agent can map each of the six asserted patents against your product’s formulation parameters, concentration ranges, and method-of-use claims — identifying relevant prior art, claim scope boundaries, and design-around opportunities. Eureka also monitors litigation and IPR filing activity across this patent family, alerting your IP team to any new enforcement actions or PTAB proceedings that could alter the risk landscape before your filing date.
Run a freedom-to-operate analysis on US11433091B2 to assess your product’s exposure
Run FTO in Eureka →Similar IV iron and ANDA patent cases in D.N.J. and beyond
Explore analogous ferric carboxymaltose, IV iron, and ANDA patent infringement actions litigated in the District of New Jersey and related federal courts.
What this case signals for the IV iron and ANDA patent IP landscape
A multi-patent no-cost dismissal in a high-value injectable iron dispute leaves enforceability intact and raises the stakes for all generic entrants.
Six uncontested patents now represent a reinforced moat around Injectafer®
No generic challenger secured an invalidity ruling in this action. The entire six-patent portfolio covering ferric carboxymaltose formulations and methods exits this litigation cycle fully intact, potentially deterring or delaying other ANDA filers who may have been watching for a court-validated invalidity defence.
Without-prejudice language with appeal waiver signals a negotiated commercial resolution
The structural tension between ‘without prejudice’ and the express finality and appeal-waiver clause is highly unusual. It strongly suggests the parties reached a private arrangement — potentially a licensing deal, supply agreement, or launch date concession — that neither party chose to disclose on the public docket.
Vifor v Dr. — key questions answered
Plaintiffs asserted six U.S. patents: US11433091B2, US11478502B2, US7754702B2, US8895612B2, US11364260B2, and US7612109B2. All relate to Injectafer® (ferric carboxymaltose injection) formulations and methods of use.
A without-prejudice dismissal means no invalidity or non-infringement finding was made. Dr. Reddy’s did not obtain a judicial ruling clearing the six patents. If it proceeds with its ANDA and launches, the same patent portfolio remains available for Vifor and American Regent to enforce in a new action.
Typically, without-prejudice dismissals allow parties to refile and do not need appeal waivers. Including an express appeal waiver and finality clause alongside without-prejudice language is structurally atypical and strongly suggests the parties reached a private commercial arrangement they wished to lock in without judicial review.
Plaintiffs were represented by Gibson, Dunn & Crutcher LLP; McCarter & English LLP; and Quinn Emanuel Urquhart & Sullivan LLP. Defendants were represented by Rivkin Radler LLP. The plaintiff-side roster of three elite firms signals the high commercial stakes Vifor and American Regent attached to this litigation.
The public docket does not disclose a claim construction order or substantive merits ruling. The 404-day period is longer than a purely procedural dismissal would typically require, suggesting discovery or pre-trial motion practice occurred, but the full extent of those proceedings is not reflected in the available public record.
PatSnap Eureka searches patents and litigation data to answer instantly.